Skip to content
10-Q

Quarterly Report

TVARDI THERAPEUTICS, INC. TVRD

0001558370-25-007575

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 8, 2025 9.36M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $34.22M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $37.9M
Current Liabilities Q1 2025 · Mar 31, 2025 $1.2M
Current Liabilities Q1 2025 · Dec 31, 2024 $3.97M
Total Liabilities Q1 2025 · Mar 31, 2025 $47.02M
Total Liabilities Q1 2025 · Dec 31, 2024 $48.42M
Total Assets Q1 2025 · Mar 31, 2025 $38.95M
Total Assets Q1 2025 · Dec 31, 2024 $43.83M
Revenue Q1 2025 · Mar 31, 2025 $2.57M
Revenue Q1 2025 · Mar 31, 2024 $2.14M
Shares Diluted restated Q1 2025 · Mar 31, 2024 1.52M sh
Capex Q1 2025 · Mar 31, 2024 $836K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$30.45M
Stockholders Equity Q1 2025 · Mar 31, 2024 $29.8M
Stockholders Equity Q1 2025 · Dec 31, 2023 $57.09M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$20.24
Eps Basic restated Q1 2025 · Mar 31, 2024 −$20.24
Sga Expense Q1 2025 · Mar 31, 2024 $6.82M
Rd Expense Q1 2025 · Mar 31, 2024 $21.96M
Net Income Q1 2025 · Mar 31, 2024 −$30.7M
Operating Income Q1 2025 · Mar 31, 2024 −$29.67M